JoVE - Journal of Visualized Experiments
JoVE Visualize
Contact Us

ZFC3H1 as an Indicator of Poor Prognosis in Hepatocellular Carcinoma: Bioinformatic Analysis and Experimental Verification

  • 0Department of Hepatobiliary and Pancreatic Surgery, Department of Surgery, Fourth Affiliated Hospital, School of Medicine, Zhejiang University, Yiwu, Zhejiang, 322000, China.
Combinatorial Chemistry & High Throughput Screening +

|

August 7, 2024

|

August 7, 2024

View abstract on PubMed

Summary

This summary is machine-generated.

Zinc finger C3H1-type containing (ZFC3H1) is elevated in liver cancer, promoting tumor growth and migration. Targeting ZFC3H1 may improve hepatocellular carcinoma (HCC) prognosis and immunotherapy response.

Area Of Science

  • Oncology
  • Molecular Biology
  • Genetics

Background

  • Zinc finger C3H1-type containing (ZFC3H1) protein's role in RNA regulation is known, but its prognostic significance in hepatocellular carcinoma (HCC) remains unclear.
  • Limited research exists on the specific impact of ZFC3H1 on HCC development and patient outcomes.

Purpose Of The Study

  • To investigate the prognostic value of ZFC3H1 expression in hepatocellular carcinoma (HCC).
  • To explore the functional role of ZFC3H1 in HCC cell proliferation, migration, and the tumor microenvironment.

Main Methods

  • Analysis of ZFC3H1 expression in HCC using transcriptomics, immunohistochemistry, and qPCR.
  • Functional assays (proliferation, migration, cell cycle) and bioinformatic analyses (GO, KEGG, ESTIMATE) were performed.
  • Correlation of ZFC3H1 expression with patient prognosis, tumor mutational burden (TMB), and immunotherapy response was assessed.

Main Results

  • ZFC3H1 is significantly upregulated in HCC and correlates with advanced tumor progression.
  • High ZFC3H1 expression serves as a negative prognostic factor for HCC patients.
  • ZFC3H1 influences the tumor microenvironment, potentially reducing immune infiltration and increasing TMB, impacting immunotherapy efficacy and sorafenib response.

Conclusions

  • ZFC3H1 promotes HCC cell proliferation and migration, negatively affecting patient prognosis.
  • ZFC3H1 represents a potential therapeutic target and a valuable biomarker for hepatocellular carcinoma.
  • Modulating ZFC3H1 expression could enhance HCC treatment strategies, including immunotherapy.

Keywords: